These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 29368539)

  • 1. Safety and efficacy of ADS-5102 (amantadine) extended release capsules to improve walking in multiple sclerosis: A randomized, placebo-controlled, phase 2 trial.
    Cohen JA; Hunter SF; Brown TR; Gudesblatt M; Thrower BW; Llorens L; Souza-Prien CJ; Ruby AE; Chernoff DN; Patni R
    Mult Scler; 2019 Apr; 25(4):601-609. PubMed ID: 29368539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase 3, double-blind, placebo-controlled efficacy and safety study of ADS-5102 (Amantadine) extended-release capsules in people with multiple sclerosis and walking impairment.
    Cohen JA; Cameron MH; Goldman MD; Goodman AD; Miller AE; Rollins A; Llorens L; Patni R; Elfont R; Johnson R
    Mult Scler; 2022 Apr; 28(5):817-830. PubMed ID: 34449295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of dyskinesia on activities of daily living in Parkinson's disease: Results from pooled phase 3 ADS-5102 clinical trials.
    Pahwa R; Isaacson S; Jimenez-Shaheed J; Malaty IA; Deik A; Johnson R; Patni R
    Parkinsonism Relat Disord; 2019 Mar; 60():118-125. PubMed ID: 30292734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study).
    Pahwa R; Tanner CM; Hauser RA; Sethi K; Isaacson S; Truong D; Struck L; Ruby AE; McClure NL; Went GT; Stempien MJ
    Mov Disord; 2015 May; 30(6):788-95. PubMed ID: 25650051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of ADS-5102 (Amantadine) Extended Release Capsules Administered Once Daily at Bedtime for the Treatment of Dyskinesia.
    Hauser RA; Pahwa R; Wargin WA; Souza-Prien CJ; McClure N; Johnson R; Nguyen JT; Patni R; Went GT
    Clin Pharmacokinet; 2019 Jan; 58(1):77-88. PubMed ID: 29777529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson's Disease.
    Tanner CM; Pahwa R; Hauser RA; Oertel WH; Isaacson SH; Jankovic J; Johnson R; Chernick D; Hubble J
    J Parkinsons Dis; 2020; 10(2):543-558. PubMed ID: 31929122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial.
    Nourbakhsh B; Revirajan N; Morris B; Cordano C; Creasman J; Manguinao M; Krysko K; Rutatangwa A; Auvray C; Aljarallah S; Jin C; Mowry E; McCulloch C; Waubant E
    Lancet Neurol; 2021 Jan; 20(1):38-48. PubMed ID: 33242419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3).
    Oertel W; Eggert K; Pahwa R; Tanner CM; Hauser RA; Trenkwalder C; Ehret R; Azulay JP; Isaacson S; Felt L; Stempien MJ
    Mov Disord; 2017 Dec; 32(12):1701-1709. PubMed ID: 28833562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine.
    Hobart J; Ziemssen T; Feys P; Linnebank M; Goodman AD; Farrell R; Hupperts R; Blight AR; Englishby V; McNeill M; Chang I; Lima G; Elkins J;
    CNS Drugs; 2019 Jan; 33(1):61-79. PubMed ID: 30535670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial.
    Pahwa R; Tanner CM; Hauser RA; Isaacson SH; Nausieda PA; Truong DD; Agarwal P; Hull KL; Lyons KE; Johnson R; Stempien MJ
    JAMA Neurol; 2017 Aug; 74(8):941-949. PubMed ID: 28604926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Dalfampridine Extended-release Tablets on 6-minute Walk Distance in Patients With Multiple Sclerosis: A Post Hoc Analysis of a Double-blind, Placebo-controlled Trial.
    Applebee A; Goodman AD; Mayadev AS; Bethoux F; Goldman MD; Klingler M; Blight AR; Carrazana EJ
    Clin Ther; 2015 Dec; 37(12):2780-7. PubMed ID: 26565077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson's Disease.
    Elmer LW; Juncos JL; Singer C; Truong DD; Criswell SR; Parashos S; Felt L; Johnson R; Patni R
    CNS Drugs; 2018 Apr; 32(4):387-398. PubMed ID: 29532440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minimally important clinical difference of the Timed 25-Foot Walk Test: results from a randomized controlled trial in patients with multiple sclerosis.
    Coleman CI; Sobieraj DM; Marinucci LN
    Curr Med Res Opin; 2012 Jan; 28(1):49-56. PubMed ID: 22073939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolonged-release fampridine in multiple sclerosis: Improved ambulation effected by changes in walking pattern.
    Zörner B; Filli L; Reuter K; Kapitza S; Lörincz L; Sutter T; Weller D; Farkas M; Easthope CS; Czaplinski A; Weller M; Linnebank M
    Mult Scler; 2016 Oct; 22(11):1463-1475. PubMed ID: 26762672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson's Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study.
    Hauser RA; Pahwa R; Tanner CM; Oertel W; Isaacson SH; Johnson R; Felt L; Stempien MJ
    J Parkinsons Dis; 2017; 7(3):511-522. PubMed ID: 28777755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial.
    Hupperts R; Lycke J; Short C; Gasperini C; McNeill M; Medori R; Tofil-Kaluza A; Hovenden M; Mehta LR; Elkins J
    Mult Scler; 2016 Feb; 22(2):212-21. PubMed ID: 25921050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose comparison trial of sustained-release fampridine in multiple sclerosis.
    Goodman AD; Brown TR; Cohen JA; Krupp LB; Schapiro R; Schwid SR; Cohen R; Marinucci LN; Blight AR;
    Neurology; 2008 Oct; 71(15):1134-41. PubMed ID: 18672472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials.
    Goodman AD; Bethoux F; Brown TR; Schapiro RT; Cohen R; Marinucci LN; Henney HR; Blight AR;
    Mult Scler; 2015 Sep; 21(10):1322-31. PubMed ID: 25583832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial.
    Goodman AD; Brown TR; Krupp LB; Schapiro RT; Schwid SR; Cohen R; Marinucci LN; Blight AR;
    Lancet; 2009 Feb; 373(9665):732-8. PubMed ID: 19249634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo.
    Krupp LB; Coyle PK; Doscher C; Miller A; Cross AH; Jandorf L; Halper J; Johnson B; Morgante L; Grimson R
    Neurology; 1995 Nov; 45(11):1956-61. PubMed ID: 7501140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.